India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#392- Valuation
- ₹13,580 Cr
2023 #310 2022 #275
Market Cap
₹15,675 Cr
MOLBIO · NSE
Share Price
₹1,336.00
-1.78% today
Revenue
₹1,446 Cr
FY 2025-26 · +41.7% YoY
EBITDA
₹315 Cr
Margin 21.8%
Net Profit
₹167 Cr
FY 2025-26 · +10.0% YoY
P/E (TTM)
92.3x
P/B 11.3x
ROE
15.4%
ROCE 19.1%
Debt / Equity
0.28
Interest cover 13.3x
About Molbio Diagnostics Limited
Data last updated:
Molbio Diagnostics Limited is a public limited company based in Salcete, Goa, India. It operates in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 20 October 2000 and has been in existence for over 26 years.
Its director Sriram Natarajan and family are #579 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Goa, under CIN U33125GA2000PLC002909. Its GSTIN is 30AACCM8275E1ZO (Goa). The company holds 7 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 544866 and NSE: MOLBIO.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹11.28 Cr. It is led by directors including Arunkumar Jha and Chandrasekhar Bhaskaran Nair.
Its last annual general meeting (AGM) was held on 11 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Plot No.L – 46 Phase II – D Verna Industrial Area Verna, Salcete, Goa, India – 403722.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,445.69 Cr, a growth of 41.7% compared to the previous year. For the same year it recorded a net profit of ₹167.18 Cr (net margin 11.6%) and EBITDA of ₹314.9 Cr (EBITDA margin 21.8%). The net worth stands at ₹1,169.34 Cr (up 20.7% YoY). Total assets are valued at ₹1,768.42 Cr (up 54.7% YoY).
The company has about 616 employees on its provident fund (EPFO) records. Its group structure includes 4 subsidiaries.
The company is associated with 2 brands: Molbio Diagnostics and Bigtec Labs. As per MCA filings, the company has open charges of ₹548.35 Cr and satisfied charges of ₹260.62 Cr on record. Court records list 3 cases involving the company, including 3 filed by the company; 1 case is pending. The company has 13 deals on record (5 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹1,271.22 Cr; the latest was in September 2026. Its 3 peer companies in the Healthcare industry (Medical and Laboratory Equipment), with the same principal business activity (other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities) are compared by revenue, 1 larger and 2 smaller; the largest is Sahajanand Medical Technologies Limited with revenue of ₹1,035.96 Cr. The company has 37 MSME Form 1 returns on record between 2006 and 2024, listing 1,735 overdue payments to 211 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website molbiodiagnostics.com.
Company details
CIN U33125GA2000PLC002909
Registration Number 002909
Incorporation Date 20 October 2000
ROC Goa
Listing Status Listed - Listed on NSE (MOLBIO); Listed on BSE (544866)
Company Status Active
Date of Last AGM 11 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Molbio Diagnostics has one previous CIN (Corporate Identification Number): U33125GA2000PTC002909. The current CIN is U33125GA2000PLC002909, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U33125GA2000PLC002909 | Current |
| U33125GA2000PTC002909 | Previous |
Recognitions & Rankings of Molbio Diagnostics
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #579 Sriram Natarajan & family ₹5,800 Cr
Contact details
Molbio Diagnostics Limited's registered office is in Salcete, Goa. Its website is molbiodiagnostics.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No.L – 46 Phase II – D Verna Industrial Area Verna, Salcete, Goa, India – 403722
- IndustryHealthcare, Medical & Laboratory Equipment
To see the full contact details of Molbio Diagnostics Limited, buy the company report.
Comprehensive company report
Molbio Diagnostics Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Molbio Diagnostics operates two associated brands: Molbio Diagnostics and Bigtec Labs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Point-of-care molecular platforms for infectious disease detection are developed. | molbiodiagnostics.com | |
| Point-of-care solutions for nucleic acid amplification tests are developed. | bigteclabs.com |
Business activity
The main business activity of Molbio Diagnostics is manufacturing. In detail, this covers other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C13 | Other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities |
To see the full business activity and turnover split of Molbio Diagnostics Limited, buy the company report.
Financials of Molbio Diagnostics Limited
FY 2025-26 filings availableMolbio Diagnostics Limited reported revenue of ₹1,445.69 Cr (up 41.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹1,446 Cr
+41.7% YoY
EBITDA
₹315 Cr
+27.0% YoY
Profit After Tax
₹167 Cr
+10.0% YoY
Net Worth
₹1,169 Cr
+20.7% YoY
Total Assets
₹1,768 Cr
+54.7% YoY
Total Debt
₹450 Cr
+206.3% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 1,446 | 1,020 | 837 |
| Revenue growth | +41.7% | +22.0% | - |
| EBITDA | 315 | 248 | 181 |
| EBITDA margin | +21.8% | +24.3% | +21.6% |
| Profit before tax | 231 | 194 | 130 |
| Net profit | 167 | 152 | 128 |
| Net profit margin | +11.6% | +14.9% | +15.3% |
| EPS (₹) | 14.77 | 64.32 | 452.32 |
| Balance sheet | |||
| Total assets | 1,768 | 1,143 | 1,039 |
| Net worth | 1,169 | 968 | 823 |
| Total debt | 450 | 147 | 184 |
| Cash & bank | 367 | 129 | 22.11 |
| Net working capital | 1,038 | 612 | 644 |
| Cash flow | |||
| Cash from operations | 50.39 | 287 | 9.57 |
| Cash from investing | (53.91) | (123) | (45.01) |
| Cash from financing | 276 | (26.15) | (31.55) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | 259 | 408 | 561 | 205 | 580 | 99.71 |
| Revenue growth (YoY) | -55.4% | +309.6% | - | - | - | - |
| Other income | 5.77 | 3.10 | 4.79 | 2.84 | 1.09 | 0.76 |
| EBITDA | 43.95 | 101 | 159 | 8.70 | 167 | (16.10) |
| EBITDA margin | +17.0% | +24.6% | +28.3% | +4.2% | +28.9% | -16.1% |
| Depreciation | 23.36 | 17.08 | 19.60 | 17.91 | 13.81 | 12.32 |
| Interest | 8.86 | 10.70 | 12.08 | 10.80 | 6.98 | 3.61 |
| Profit before tax | 17.50 | 75.91 | 132 | (17.17) | 148 | (31.27) |
| Tax | 9.80 | 23.17 | 36.01 | (2.57) | 40.89 | (7.33) |
| Net profit | 7.70 | 52.74 | 95.82 | (14.60) | 107 | (23.94) |
| EPS (₹) | 1.33 | 5.21 | 8.05 | 0.00 | 9.74 | (2.10) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1,313 | 971 | 756 | 327 | 776 | 1,271 |
| Revenue growth | +35.2% | +28.4% | +131.6% | -57.9% | -38.9% | - |
| EBITDA | 249 | 217 | 177 | 40.08 | 319 | 595 |
| EBITDA margin | +18.9% | +22.3% | +23.4% | +12.3% | +41.1% | +46.8% |
| Profit before tax | 198 | 188 | 152 | 22.85 | 258 | 549 |
| Net profit | 147 | 146 | 128 | 15.54 | 187 | 410 |
| Net profit margin | +11.2% | +15.0% | +16.9% | +4.8% | +24.1% | +32.2% |
| EPS (₹) | 12.83 | 61.98 | 492.93 | 68.97 | 833.47 | 2,026.76 |
| Balance sheet | ||||||
| Total assets | 1,486 | 1,018 | 921 | 796 | 791 | 594 |
| Net worth | 1,135 | 990 | 850 | 739 | 683 | 335 |
| Total debt | 346 | 26.20 | 70.24 | 57.18 | 105 | 257 |
| Cash & bank | 109 | 111 | 18.26 | 4.58 | 6.39 | 15.87 |
| Net working capital | 749 | 537 | 567 | 488 | 549 | 377 |
| Cash flow | ||||||
| Cash from operations | (37.98) | 249 | 37.74 | 67.90 | 97.78 | 344 |
| Cash from investing | (256) | (97.90) | (31.44) | (51.01) | (86.72) | (142) |
| Cash from financing | 292 | (17.35) | (24.20) | 30.96 | (20.01) | (192) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | 249 | 399 | 439 | 200 | 579 | 95.32 |
| Revenue growth (YoY) | -57.0% | +319.0% | - | - | - | - |
| Other income | 3.97 | 1.37 | 2.74 | 1.90 | 1.59 | 1.48 |
| Total expenses | 190 | 308 | 332 | 183 | 445 | 105 |
| EBITDA | 58.64 | 91.64 | 107 | 17.09 | 134 | (9.64) |
| EBITDA margin | +23.6% | +22.9% | +24.4% | +8.5% | +23.2% | -10.1% |
| Depreciation | 13.99 | 8.42 | 9.85 | 9.73 | 8.75 | 7.41 |
| Interest | 6.27 | 8.66 | 9.28 | 8.08 | 3.91 | 1.89 |
| Profit before tax | 42.35 | 75.93 | 90.65 | 1.18 | 123 | (17.46) |
| Tax | 10.97 | 19.30 | 24.97 | 0.11 | 31.21 | (4.06) |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | 259 | 408 | 561 | 205 | 580 | 99.71 |
| Revenue growth (YoY) | -55.4% | +309.6% | - | - | - | - |
| Other income | 5.77 | 3.10 | 4.79 | 2.84 | 1.09 | 0.76 |
| EBITDA | 43.95 | 101 | 159 | 8.70 | 167 | (16.10) |
| EBITDA margin | +17.0% | +24.6% | +28.3% | +4.2% | +28.9% | -16.1% |
| Depreciation | 23.36 | 17.08 | 19.60 | 17.91 | 13.81 | 12.32 |
| Interest | 8.86 | 10.70 | 12.08 | 10.80 | 6.98 | 3.61 |
| Profit before tax | 17.50 | 75.91 | 132 | (17.17) | 148 | (31.27) |
| Tax | 9.80 | 23.17 | 36.01 | (2.57) | 40.89 | (7.33) |
| Net profit | 7.70 | 52.74 | 95.82 | (14.60) | 107 | (23.94) |
| EPS (₹) | 1.33 | 5.21 | 8.05 | 0.00 | 9.74 | (2.10) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 1,446 | 1,020 | 837 |
| Revenue growth | +41.7% | +22.0% | - |
| Other income | 13.33 | 8.70 | 4.10 |
| Total expenses | 1,131 | 772 | 656 |
| Employee cost | 145 | 103 | 63.89 |
| EBITDA | 315 | 248 | 181 |
| EBITDA margin | +21.8% | +24.3% | +21.6% |
| Depreciation | 63.64 | 44.55 | 41.01 |
| Interest | 33.47 | 17.66 | 14.45 |
| Profit before tax | 231 | 194 | 130 |
| Tax | 66.99 | 55.85 | 46.09 |
| Net profit | 167 | 152 | 128 |
| Net profit margin | +11.6% | +14.9% | +15.3% |
| EPS (₹) | 14.77 | 64.32 | 452.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 11.28 | 2.26 | 2.25 |
| Reserves & surplus | 1,158 | 966 | 821 |
| Shareholders' funds (net worth) | 1,169 | 968 | 823 |
| Minority interest | 139 | (1.11) | 5.46 |
| Secured loans | 336 | 17.41 | 66.40 |
| Unsecured loans | 114 | 130 | 117 |
| Total debt | 450 | 147 | 184 |
| Total liabilities | 1,768 | 1,143 | 1,039 |
| Assets | |||
| Gross block | 787 | 485 | 448 |
| Net block | 536 | 290 | 289 |
| Capital work in progress | 11.32 | 27.33 | 1.58 |
| Investments | 5.98 | 45.57 | 5.99 |
| Inventories | 449 | 436 | 315 |
| Sundry debtors | 409 | 272 | 425 |
| Cash & bank balances | 367 | 129 | 22.11 |
| Loans & advances | 160 | 93.21 | 60.46 |
| Total current assets | 1,385 | 930 | 823 |
| Total current liabilities | 347 | 318 | 179 |
| Net working capital | 1,038 | 612 | 644 |
| Total assets | 1,768 | 1,143 | 1,039 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 63.23 | (75.07) | (8.08) |
| Net cash from operating activities | 50.39 | 287 | 9.57 |
| Net cash from investing activities | (53.91) | (123) | (45.01) |
| Net cash from financing activities | 276 | (26.15) | (31.55) |
| Net change in cash | 273 | 138 | (66.99) |
| Closing cash | 367 | 129 | 22.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +41.7% | +22.0% | - |
| EBITDA growth | +27.0% | +37.0% | - |
| PBT growth | +18.9% | +50.0% | +9997.0% |
| Net income growth | +10.0% | +18.4% | - |
| Profitability & leverage | |||
| Net income margin | +11.4% | +13.6% | +10.0% |
| Return on capital employed | +19.1% | +19.5% | +20.7% |
| Return on net worth | +15.4% | +15.5% | +14.2% |
| Debt / equity | 0.28 | 0.18 | 0.20 |
| Long-term debt / equity | 0.12 | 0.02 | 0.05 |
| Interest cover | 13.32 | 8.68 | 10.32 |
| Efficiency & per share | |||
| Fixed asset turnover | 2.27 | 2.19 | 2.00 |
| Inventory turnover | 3.27 | 2.72 | 2.53 |
| Debtors turnover | 4.25 | 2.93 | 2.72 |
| EPS (₹) | 14.77 | 64.32 | 452.32 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 103.70 | 429.25 | 3,651.42 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | 249 | 399 | 439 | 200 | 579 | 95.32 |
| Revenue growth (YoY) | -57.0% | +319.0% | - | - | - | - |
| Other income | 3.97 | 1.37 | 2.74 | 1.90 | 1.59 | 1.48 |
| Total expenses | 190 | 308 | 332 | 183 | 445 | 105 |
| EBITDA | 58.64 | 91.64 | 107 | 17.09 | 134 | (9.64) |
| EBITDA margin | +23.6% | +22.9% | +24.4% | +8.5% | +23.2% | -10.1% |
| Depreciation | 13.99 | 8.42 | 9.85 | 9.73 | 8.75 | 7.41 |
| Interest | 6.27 | 8.66 | 9.28 | 8.08 | 3.91 | 1.89 |
| Profit before tax | 42.35 | 75.93 | 90.65 | 1.18 | 123 | (17.46) |
| Tax | 10.97 | 19.30 | 24.97 | 0.11 | 31.21 | (4.06) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 1,313 | 971 | 756 | 327 | 776 | 1,271 |
| Revenue growth | +35.2% | +28.4% | +131.6% | -57.9% | -38.9% | - |
| Other income | 7.72 | 6.37 | 6.52 | 8.10 | 5.11 | 1.48 |
| Total expenses | 1,065 | 754 | 580 | 286 | 457 | 676 |
| Employee cost | 0.00 | 65.65 | 38.60 | 34.01 | 28.81 | 77.81 |
| EBITDA | 249 | 217 | 177 | 40.08 | 319 | 595 |
| EBITDA margin | +18.9% | +22.3% | +23.4% | +12.3% | +41.1% | +46.8% |
| Depreciation | 35.73 | 26.31 | 23.60 | 19.39 | 41.75 | 12.03 |
| Interest | 23.15 | 8.86 | 7.61 | 5.94 | 24.86 | 35.24 |
| Profit before tax | 198 | 188 | 152 | 22.85 | 258 | 549 |
| Tax | 52.92 | 48.22 | 40.79 | 7.31 | 70.57 | 139 |
| Net profit | 147 | 146 | 128 | 15.54 | 187 | 410 |
| Net profit margin | +11.2% | +15.0% | +16.9% | +4.8% | +24.1% | +32.2% |
| EPS (₹) | 12.83 | 61.98 | 492.93 | 68.97 | 833.47 | 2,026.76 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 11.28 | 2.26 | 2.25 | 2.25 | 2.25 | 2.02 |
| Reserves & surplus | 1,123 | 988 | 847 | 736 | 681 | 333 |
| Shareholders' funds (net worth) | 1,135 | 990 | 850 | 739 | 683 | 335 |
| Secured loans | 335 | 17.41 | 25.58 | 37.98 | 1.31 | 157 |
| Unsecured loans | 11.38 | 8.79 | 44.66 | 19.20 | 104 | 99.33 |
| Total debt | 346 | 26.20 | 70.24 | 57.18 | 105 | 257 |
| Total liabilities | 1,486 | 1,018 | 921 | 796 | 791 | 594 |
| Assets | ||||||
| Gross block | 407 | 333 | 300 | 260 | 234 | 66.17 |
| Net block | 257 | 215 | 209 | 189 | 182 | 54.81 |
| Capital work in progress | 5.62 | 17.60 | 1.58 | 0.00 | 0.00 | 100 |
| Investments | 317 | 95.35 | 53.79 | 53.79 | 8.74 | 8.74 |
| Inventories | 397 | 410 | 293 | 328 | 296 | 265 |
| Sundry debtors | 359 | 228 | 360 | 173 | 241 | 211 |
| Cash & bank balances | 109 | 111 | 18.26 | 4.58 | 6.39 | 15.87 |
| Loans & advances | 139 | 77.79 | 52.38 | 105 | 88.90 | 96.91 |
| Total current assets | 1,004 | 827 | 724 | 611 | 632 | 589 |
| Total current liabilities | 254 | 290 | 157 | 123 | 82.79 | 213 |
| Net working capital | 749 | 537 | 567 | 488 | 549 | 377 |
| Total assets | 1,486 | 1,018 | 921 | 796 | 791 | 594 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 111 | (22.56) | (4.65) | (52.49) | 14.95 | 5.37 |
| Net cash from operating activities | (37.98) | 249 | 37.74 | 67.90 | 97.78 | 344 |
| Net cash from investing activities | (256) | (97.90) | (31.44) | (51.01) | (86.72) | (142) |
| Net cash from financing activities | 292 | (17.35) | (24.20) | 30.96 | (20.01) | (192) |
| Net change in cash | (1.84) | 133 | (17.91) | 47.84 | (8.94) | 9.58 |
| Closing cash | 109 | 111 | 18.26 | 4.58 | 6.39 | 15.87 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +35.2% | +28.4% | +131.6% | -57.9% | -38.9% | - |
| EBITDA growth | +14.7% | +22.8% | +340.6% | -87.5% | -46.3% | - |
| PBT growth | +5.1% | +23.8% | +564.7% | -91.1% | -53.1% | +9997.0% |
| Net income growth | +0.9% | +13.7% | +723.9% | -91.7% | -54.3% | - |
| Revenue CAGR (3Y) | +59.0% | +7.8% | -15.9% | - | - | - |
| EBITDA CAGR (3Y) | +83.8% | -12.1% | -33.3% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +11.0% | +14.4% | +14.7% | +4.8% | +24.1% | +32.2% |
| Return on capital employed | +17.6% | +20.3% | +21.8% | +3.6% | +40.8% | +127.4% |
| Return on net worth | +13.6% | +15.2% | +16.1% | +2.2% | +36.8% | +310.6% |
| Debt / equity | 0.18 | 0.05 | 0.08 | 0.11 | 0.36 | 2.47 |
| Long-term debt / equity | 0.11 | 0.02 | 0.01 | 0.00 | 0.16 | 1.48 |
| Interest cover | 10.87 | 4.65 | 4.97 | 28.71 | 8.96 | 6.05 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 3.55 | 3.07 | 2.70 | 1.32 | 5.17 | 21.09 |
| Inventory turnover | 3.25 | 2.76 | 2.44 | 1.05 | 2.77 | 7.88 |
| Debtors turnover | 4.48 | 3.30 | 2.83 | 1.58 | 3.43 | 10.92 |
| EPS (₹) | 12.83 | 61.98 | 492.93 | 68.97 | 833.47 | 2,026.76 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 100.63 | 438.86 | 3,769.45 | 3,276.95 | 3,042.22 | 1,655.09 |
To see the full year-wise statements and ratios of Molbio Diagnostics Limited, buy the company report.
Board of directors and KMP of Molbio Diagnostics Limited
Molbio Diagnostics Limited currently reports 5 directors and 1 key managerial person. 13 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arunkumar Jha Also directs: Molbio Diagnostics Limited | Director | 16 Nov 2024 | 1 Years 11 Months | Current |
| Chandrasekhar Bhaskaran Nair Also directs: Molbio Diagnostics Limited, Bigtec Private Limited, Prognosys Medical Systems Private Limited and 5 more | Director | 01 Aug 2011 | 15 Years 3 Months | Current |
| Balram Bhargava Also directs: Molbio Diagnostics Limited, Cipla Limited | Director | 16 Nov 2024 | 1 Years 11 Months | Current |
| Nupur Garg | Director | 31 Jan 2025 | 1 Years 9 Months | Current |
| Sriram Natarajan Also directs: Exxora Trading LLP, Molbio Diagnostics Limited, Coreintegra Consulting Services Limited and 5 more | Ceo | 10 Jul 2023 | 3 Years 3 Months | Current |
| Sangeetha Sriram Also directs: Exxora Trading LLP, Molbio Diagnostics Limited, Coreintegra Consulting Services Limited and 5 more | Director | 19 Jun 2020 | 6 Years 4 Months | Current |
Peer comparison
Molbio Diagnostics Limited is compared with the 3 companies closest to it by revenue in the Healthcare industry (Medical and Laboratory Equipment), with the same principal business activity (other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Molbio Diagnostics Limitedthis company | ₹1,445.69 Cr (FY 2026) | ₹167.18 Cr | 11.6% | 41.7% | 616 | Salcete, Goa, India |
| Sahajanand Medical Technologies Limited | ₹1,035.96 Cr (FY 2025) | 14.0% | Surat, Gujarat, India | |||
| Romsons Group Private Limited | ₹875.1 Cr (FY 2024) | 5.0% | Uttar Pradesh, India | |||
| Allengers Medical Systems Limited | ₹873.71 Cr (FY 2025) | 3.0% | New Delhi, Delhi, India |
To see the full peer comparison of Molbio Diagnostics Limited, buy the company report.
Auditor
Molbio Diagnostics Limited is audited by S. R. Batliboi & Associates LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S. R. Batliboi & Associates LLP | FY 2023 | 101049W/E300004 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 41.30%, foreign institutional investors hold 1.60%, domestic institutional investors hold 19.10% and retail and other public shareholders hold 38.00%.
Sep 2026
QUARTER
41.30% Promoters
19.10% DII (Domestic Institutional)
1.60% FII (Foreign Institutional)
38.00% Retail & Others
Shareholding trend - last 6 quarters
| Sep 2026 | |
|---|---|
| Promoters | 41.30% |
| Public | 58.70% |
Charges & borrowings
Open charges
₹548.35 Cr
Satisfied charges
₹260.62 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 Oct 2025 | 101178376 | Others | ₹225.9 Cr | Open | |
| 27 Feb 2025 | 101061746 | Axis Bank Limited | ₹45 Cr | Open | |
| 17 Jul 2024 | 100989051 | Others | ₹2.75 Cr | Open | |
| 05 Dec 2023 | 100861038 | Others | ₹100 Cr | Open | |
| 12 Oct 2023 | 100807400 | Tata Capital Financial Services Limited | ₹45 Cr | Open |
To see the full charge records of Molbio Diagnostics Limited, buy the company report.
Total charge records: 16 View all charges
Deals & funding
Molbio Diagnostics Limited has 13 deals on record (5 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹1,271.22 Cr; the latest was in September 2026.
Total deals
13
Secondary share transfers
5
Funding rounds
3
Rights issue
1
Convertible or debt financing
1
Disclosed funding
₹1,271.22 Cr
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2026 | Market trade | ₹394.08 Cr | Buyer: Kotak Mahindra Mutual Fund Seller: Business Excellence Trust Iii |
| Aug 2026 | IPO | ₹939.85 Cr | Investors: International Finance Corporation, HDFC Life Insurance Company Limited , Bajaj Life Insurance Limited Seller: Exxora Trading LLP , India Business Excellence Fund III, 2 individuals |
| Sep 2024 | Funding round | ₹1 Cr | Investors: an individual |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: Bigtec Innovations Private Limited |
| Dec 2015 | Secondary share transfer | Undisclosed | Buyer: Bigtec Innovations Private Limited Seller: Bigtec Private Limited |
To see the full deal history of Molbio Diagnostics Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Molbio Diagnostics Limited has 3 court cases on record: 3 filed by Molbio Diagnostics. 1 case is pending and 2 are disposed.
Total cases
3
Filed by the company
3
Pending
1
Disposed
2
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 3 | 0 | 1 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Writ petition | Filed by the company against The Union of India THR. the Revenue Secretary and 3 Ors | Pending |
| Bombay High Court | Court case (COP) | Filed by the company | Disposed |
| Bombay High Court | Court case (COAPM) | Filed by the company | Disposed |
To see the full case history of Molbio Diagnostics Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Molbio Diagnostics Limited has 37 MSME Form 1 returns on record between 2006 and 2024, listing 1,735 overdue payments to 211 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 211)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Innoprime Plast Private Limited | |||
| Packwell Technologies | |||
| Lensel Optics Private Limited | |||
| Handiman Services Limited | |||
| Chavan Packaging |
To see the full MSME payment records of Molbio Diagnostics Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Molbio Diagnostics has 4 subsidiary companies and 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
4
Subsidiary companies
1
Associated companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Remfuel Bioenergy Private Limited | U40102KA2008PTC048395 | |
| Bigtec Private Limited | U65192KA1996PTC020736 | |
| Deciphar Life Sciences Private Limited | U74140KA2001PTC029114 | |
| Bigtec Healthcare Private Limited | U85195KA2011PTC058084 |
To see the full group structure of Molbio Diagnostics Limited, buy the company report.
Employees & EPFO
Molbio Diagnostics Limited has a workforce of 616 employees on its EPFO records as of Apr 20, 2024, across 1 active EPFO establishment.
Employee count
616
Active EPFO establishments
1
Employee growth
11.8%
GST
Molbio Diagnostics has 7 GST registrations: 7 active. The first 4 active GSTINs are listed below.
Total GSTINs
7
Active
7
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 30AACCM8275E1ZO | Goa | Active | 01 Jul 2017 |
| 29AACCM8275E1Z7 | Karnataka | Active | 19 Jul 2017 |
| 37AACCM8275E1ZA | Andhra Pradesh | Active | 15 Nov 2018 |
| 27AACCM8275E1ZB | Maharashtra | Active | 18 Apr 2023 |
To see the full GST registrations and return filing status of Molbio Diagnostics Limited, buy the company report.
Recent activity
Molbio Diagnostics Limited has 19 board changes on record since 2011: 6 appointments and 13 cessations. The latest: Amol Narayan Lone ceased to be CFO on 09 Dec 2025.
Filing
Molbio Diagnostics Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Goa.
Ceased
Amol Narayan Lone ceased to be CFO.
Charges
A charge with Yes Bank Limited of Rs. 127.75 Cr registered on 23 Dec 2022 with Charge ID 100665188 was modified on 04 Nov 2025.
Charges
A charge with Others amounted to Rs. 225.90 Cr with Charge ID 101178376 was registered on 25 Oct 2025.
Charges
A charge with Axis Bank Limited of Rs. 45.00 Cr registered on 27 Feb 2025 with Charge ID 101061746 was modified on 30 Sep 2025.
Charges
A charge with Others of Rs. 100.00 Cr registered on 05 Dec 2023 with Charge ID 100861038 was modified on 05 Sep 2025.
AGM
Molbio Diagnostics Limited last Annual general meeting of members was held on 11 Aug 2025 as per latest MCA records.
Ceased
Nupur Garg ceased to be Additional Director.
Ceased
Ved Prakash Kalanoria ceased to be Nominee Director.
Charges
A charge with Axis Bank Limited amounted to Rs. 45.00 Cr with Charge ID 101061746 was registered on 27 Feb 2025.
Charges
A charge registered on 03 Nov 2023 via Charge ID 100818122 with Others was fully satisfied on 07 Feb 2025.
Appointed
Nupur Garg was appointed as Director.
39 earlier events are in the company report.
News
Frequently asked questions
Molbio Diagnostics is an active public limited company based in Salcete, Goa, India. The company works in medical and laboratory equipment, within the healthcare industry. It was incorporated on 20 October 2000 (26+ years old) and is registered under CIN U33125GA2000PLC002909. Listed on BSE: 544866 and NSE: MOLBIO.
Molbio Diagnostics reported revenue of ₹1,445.69 Cr for FY 2025-26 (up 41.7% YoY) based on consolidated financials.
Molbio Diagnostics has 6 current directors and KMP:
- Arunkumar Jha - Director
- Chandrasekhar Bhaskaran Nair - Director
- Balram Bhargava - Director
- Nupur Garg - Director
- Sangeetha Sriram - Director
- Sriram Natarajan - Ceo
The latest financial statements of Molbio Diagnostics on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 11 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Molbio Diagnostics is 30AACCM8275E1ZO, registered in Goa. The company has 7 GST registrations in all, of which 7 are active. Other active GSTINs include 29AACCM8275E1Z7 (Karnataka), 37AACCM8275E1ZA (Andhra Pradesh), 27AACCM8275E1ZB (Maharashtra).
The CIN (Corporate Identification Number) of Molbio Diagnostics is U33125GA2000PLC002909. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Molbio Diagnostics is a listed company as per MCA records. Its shares are listed on both BSE (code: 544866) and NSE (symbol: MOLBIO).
Molbio Diagnostics has 3 court cases on record: 3 filed by the company. 1 is pending.
Molbio Diagnostics was incorporated on 20 October 2000, making it 26+ years old. It is registered with the Registrar of Companies, Goa.
Molbio Diagnostics has 13 deals on record (5 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹1,271.22 Cr; the latest was in September 2026.
The peers of Molbio Diagnostics by revenue are Sahajanand Medical Technologies Limited, Romsons Group Private Limited, Allengers Medical Systems Limited, all in the Healthcare industry (Medical and Laboratory Equipment), with the same principal business activity (other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities).
Amol Narayan Lone ceased to be CFO on 09 Dec 2025. Nupur Garg ceased to be Additional Director on 10 Aug 2025. Ved Prakash Kalanoria ceased to be Nominee Director on 10 Aug 2025. Molbio Diagnostics has 19 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages